873655-56-2Relevant academic research and scientific papers
DIHYDROOROTATE DEHYDROGENASE INHIBITORS
-
, (2020/07/25)
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, and R3, are defined herein.
DIHYDROOROTATE DEHYDROGENASE INHIBITORS
-
, (2020/08/22)
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Embodiments of such compounds are represented by Formula (I) as follows: 5 wherein R1, R2, R3, R4, R5a, R5b, X and Y, are defined herein.
DIHYDROOROTATE DEHYDROGENASE INHIBITORS
-
, (2020/10/28)
Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R4, X, and Y are defined herein.
SOLID STATE FORMS OF FUSED HETEROAROMATIC PYRROLIDINONES
-
Paragraph 0367-0368, (2016/07/05)
Disclosed are chemical entities which are inhibitors of spleen tyrosine kinase (SYK), namely, chemical entities comprising 6-((lR,2S)-2-aminocyclohexylamino)-7-fluoro-4-(1 -methyl-1H- pyrazol-4-yl)-lH-pyrrolo[3,4-c]pyridine-3(2H)-one and certain solid state forms thereof. Also disclosed are methods of using the chemical entities to treat disorders such as a cancer.
